Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899204 | 0.91 | DRD4 (0.57) | DRD2DRD4MAPTNPC1LMNA | |
| SCHEMBL8614711 | 0.84 | ALDH1A1 (0.61) | DRD2MAPTNPC1LMNAHTT | |
| SCHEMBL21712168 | 0.80 | DRD2 (0.64) | DRD2DRD4MAPTNPC1LMNA | |
| SCHEMBL30912017 | 0.80 | DRD2 (0.64) | DRD2DRD4MAPTNPC1LMNA | |
| SCHEMBL5899203 | 0.79 | DRD4 (0.52) | DRD4MAPTNPC1LMNAHTT | |
| SCHEMBL27872558 | 0.78 | DRD2 (0.57) | DRD2DRD4MAPTNPC1LMNA | |
| SCHEMBL6966940 | 0.78 | DRD2 (0.61) | DRD2DRD4MAPTNPC1LMNA | |
| SCHEMBL5803986 | 0.77 | HPGD (0.70) | NPC1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL3735431 | 0.77 | DRD2 (0.56) | DRD2DRD4MAPTNPC1LMNA | |
| SCHEMBL981641 | 0.76 | NOTUM (0.60) | DRD2MAPTNPC1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183902-A1 | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183902-A1 | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | ADRA1D, ADRA1A, ADRB1 | DRD2 301/4885DRD4 367/4885MAPT 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.